Medications like Ozempic®, Wegovy®, and Mounjaro® have quickly moved from niche treatments for type 2 diabetes to headline-grabbing tools for weight management.

Amet mauris lectus a facilisi elementum ornare id sed sed aliquet dolor elementum magnis quisque id ultrices viverra cursus nunc odio in egestas consectetur cras consequat sodales netus pretium feugiat nulla semper senectus bibendum ornare sit adipiscing ut atid viverra donec nunc, donec pulvinar enim ac habitasse fermentum amet praesent atac elementum id sed nibh diam ultrices nibh enim volutpat varius et est sed vestibulum neque.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Vitae congue eu consequat ac felis placerat vestibulum lectus mauris ultrices cursus sit amet dictum sit amet justo donec enim diam porttitor lacus luctus accumsan tortor posuere praesent tristique magna sit amet purus gravida quis blandit turpis.

Ornare sit adipiscing ut atid viverra donec nunc, donec pulvinar enim ac habitasse fermentum amet nunc praesent atac elementum id sed nibh diam ultrices nibh enim volutpat varius et est sed vestibulum neque.
Amet mauris lectus a facilisi elementum ornare id sed sed aliquet dolor elementum magnis quisque id ultrices viverra cursus nunc odio in egestas consectetur cras consequat sodales netus pretium feugiat nulla semper senectus bibendum.
“Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur excepteur sint occaecat cupidatat non proident, sunt in culpa qui offi.”
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Medications like Ozempic®, Wegovy®, and Mounjaro® have quickly moved from niche treatments for type 2 diabetes to headline-grabbing tools for weight management.
What Are GLP-1 Medications — and Why Are They So Popular?
GLP-1 receptor agonists are a class of medications originally developed to help people with type 2 diabetes control blood sugar. But recent clinical trials have shown additional benefits, including:
Because of these effects, GLP-1s have gained FDA approval (or are under review) for weight management, even in patients without diabetes —and demand is soaring.
What Patients Need to Know
At PBACO, we recognize that interest in these medications is growing — but so are the questions.
Is this right for me?
GLP-1s aren’t one-size-fits-all. Seniors with complex health needs may have risks (such as gastrointestinal issues, muscle loss, or malnutrition) that need to be weighed carefully.
Can I stay on this long-term?
Most studies suggest weight returns when the medication is stopped. That’s why lifestyle, nutrition, and care planning must be part of the conversation.
Is it covered?
GLP-1 medications can cost $1,000+ per month and may not be covered by all Medicare plans. Our care teams help patients explore affordability, coverage options, and alternatives.
PBACO’s Coordinated Care Approach to GLP-1s
Rather than treat these prescriptions as quick fixes, PBACO takes a team-based approach:
Why It Matters
In our aging population, chronic conditions like diabetes, obesity ,and heart disease are common — but so is polypharmacy and frailty. That’s why we’re urging caution, coordination, and ongoing patient education before starting or stopping any new therapy.
PBACO providers are trained to ask the right questions, monitor outcomes, and ensure that GLP-1 use fits into a safe, personalized care plan —not just a trend.
Final Thought: It’s Not Just About a Prescription. It’s About a Plan.
At PBACO, we don’t chase headlines — we follow science, support the whole person, and help patients make informed choices. Whether you’re a provider seeing a rise in patient requests, or a patient considering your options, we’re here to guide the journey.